First Capital Advisors Group, Llc. Vaxcyte, Inc. Transaction History
First Capital Advisors Group, Llc.
- $188 Million
- Q2 2023
A detailed history of First Capital Advisors Group, Llc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, First Capital Advisors Group, Llc. holds 100 shares of PCVX stock, worth $8,405. This represents 0.0% of its overall portfolio holdings.
Number of Shares
100Holding current value
$8,405% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PCVX
# of Institutions
276Shares Held
97.4MCall Options Held
202KPut Options Held
147K-
Vanguard Group Inc Valley Forge, PA9.74MShares$818 Million0.01% of portfolio
-
Black Rock Inc. New York, NY9.51MShares$800 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X07.67MShares$645 Million0.29% of portfolio
-
Wellington Management Group LLP Boston, MA4.92MShares$413 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.14MShares$348 Million0.07% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.99B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...